MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

PloS One
J H C M KreijtzG F Rimmelzwaan

Abstract

Human infections with highly pathogenic avian influenza viruses of the H5N1 subtype, frequently reported since 2003, result in high morbidity and mortality. It is feared that these viruses become pandemic, therefore the development of safe and effective vaccines is desirable. MVA-based H5N1 vaccines already proved to be effective when two immunizations with high doses were used. Dose-sparing strategies would increase the number of people that can be vaccinated when the amount of vaccine preparations that can be produced is limited. Furthermore, protective immunity is induced ideally after a single immunization. Therefore the minimal requirements for induction of protective immunity with a MVA-based H5N1 vaccine were assessed in mice. To this end, mice were vaccinated once or twice with descending doses of a recombinant MVA expressing the HA gene of influenza virus A/Vietnam/1194/04. The protective efficacy was determined after challenge infection with the homologous clade 1 virus and a heterologous virus derived from clade 2.1, A/Indonesia/5/05 by assessing weight loss, virus replication and histopathological changes. It was concluded that MVA-based vaccines allowed significant dose-sparing and afford cross-clade protection, al...Continue Reading

References

Feb 1, 1975·The Veterinary Record·G A ThorntonM K Fuller
Aug 1, 1989·The Journal of Infectious Diseases·J M Katz, R G Webster
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·I M BelyakovJ A Berzofsky
Jul 27, 2002·Emerging Infectious Diseases·Suzanne L EpsteinJacqueline M Katz
Dec 13, 2002·Journal of Virology·Zhi-yong YangGary J Nabel
Oct 8, 2003·Current Drug Targets. Infectious Disorders·Gerd Sutter, Caroline Staib
Dec 4, 2003·Science·Richard J Webby, Robert G Webster
Nov 25, 2004·Current Opinion in Biotechnology·Ingo DrexlerGerd Sutter
Feb 24, 2006·Emerging Infectious Diseases·Peter Palese
Jun 3, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard HarropMiles W Carroll
Apr 8, 2009·Expert Review of Vaccines·Guus F Rimmelzwaan, Gerd Sutter

❮ Previous
Next ❯

Citations

Oct 19, 2011·Journal of Biomedicine & Biotechnology·Marine L B HillaireGuus F Rimmelzwaan
Sep 7, 2011·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Ab OsterhausGuus Rimmelzwaan
Feb 26, 2014·BMC Public Health·Harish NairHarry Campbell
May 14, 2010·Animal Health Research Reviews·Wenjun Ma, Jürgen A Richt
Feb 6, 2013·Chest·Margarita M Gomez Lorenzo, Matthew J Fenton
Oct 4, 2011·Virus Research·J H C M KreijtzG F Rimmelzwaan
Aug 20, 2010·The Journal of General Virology·Joost H C M KreijtzGuus F Rimmelzwaan
Aug 9, 2011·Vaccine·Guus F RimmelzwaanAlbert D M E Osterhaus
Jul 28, 2016·Human Vaccines & Immunotherapeutics·Rory D de Vries, Guus F Rimmelzwaan
Nov 19, 2010·The New England Journal of Medicine·Linda C Lambert, Anthony S Fauci
Jul 26, 2018·Vaccines·Rory D de VriesMathilde Richard
Jun 28, 2012·Molecular Medicine·Teresa Lambe
Apr 2, 2020·Vaccines·Takashi ItoTetsuo Nakayama
Sep 29, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·John Steel
Oct 1, 2021·The Journal of Infectious Diseases·Tanja BeckerAlbert D M E Osterhaus

❮ Previous
Next ❯

Datasets Mentioned

BETA
GMT

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.